2. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. continues to expand its leadership across oncology and immunology. On April 10, Piper Sandler reiterated an Overweight rating with a $875 price target following its Integrated Oncology Day event.
The event highlighted strong optimism around BCMA T-cell engagers moving into second-line treatment, supported by MAJESTEC-3 data. Experts indicated confidence in treatment sequencing alongside CAR-T therapies.
On April 8, Cantor Fitzgerald also maintained an Overweight rating with an $800 price target. The firm expects upcoming fianlimab data to be a key driver of sentiment in 2026.
For the first quarter, expectations include stable performance from Eylea HD and slight variability in Dupixent sales. Despite near-term fluctuations, the company’s diversified portfolio across oncology, ophthalmology, and immunology supports long-term growth.
Regeneron’s strength lies in its ability to consistently generate new therapies while maintaining strong revenue from established products.
Click next to see the following stock...
